Drug Profile


Alternative Names: CAS 936

Latest Information Update: 10 Nov 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis
  • Class Anti-ischaemics; Small molecules; Sydnones; Vasodilators
  • Mechanism of Action Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Angina pectoris; Isolated systolic hypertension

Most Recent Events

  • 10 Nov 1999 No-Development-Reported for Angina pectoris in Germany (PO)
  • 10 Nov 1999 No-Development-Reported for Angina pectoris in USA (PO)
  • 10 Nov 1999 No-Development-Reported for Isolated systolic hypertension (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top